Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: REPL stock price vs BSX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BSX's multiple
Needs Annual EPS, BSX P/E.
Implied fair value · at REPL's multiple
Needs Annual EPS, REPL P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Replimune Group, Inc. · implied price per share
Reporting currency could not be verified.
BOSTON SCIENTIFIC CORP · implied price per share
Reporting currency could not be verified.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
REPL · not enough data.
BSX · not enough data.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
REPL vs AMGN
INCYTE CORP
REPL vs INCY
Blueprint Medicines Corp
REPL vs BPMC
Adaptive Biotechnologies Corp
REPL vs ADPT
Abbott Laboratories
REPL vs ABT
Johnson & Johnson
REPL vs JNJ
Intuitive Surgical, Inc.
REPL vs ISRG
STRYKER CORP
REPL vs SYK
ZIMMER BIOMET HOLDINGS, INC.
REPL vs ZBH
Edwards Lifesciences Corp
REPL vs EW
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe REPL can improve execution and eventually translate its clinical/operating base into sustained profitability, then hold or consider exposure only selectively because the stock is not far from its historical range and the current valuation is already supported more by optionality than by fundamentals.
REPL trades at $11.58, which sits within its historical band of $10.42 to $12.74, so the stock is not obviously dislocated versus its own history. On a relative basis, REPL looks optically cheaper than BSX on P/E (-3.4x vs 23.3x) and EV/EBITDA (-2.5x vs 14.0x), but those multiples are not directly comparable because REPL has negative net income and much of its revenue/EV data is unavailable.
Supporting Metrics
